BRIEF—Healx hires new COO

Cambridge, UK-based rare disease specialist Healx has appointed Kate Hilyard as chief operating officer, charged with leading “strategy implementation to drive business growth.”

Dr Hilyard has previously held senior leadership roles at BioFocus DPI and Cambridge Antibody Technology, which is now part of MedImmune.

Chief executive Tim Guilliams said: “Having started Healx with an artificial intelligence and patient care focus, Kate’s appointment broadens our senior expertise with further deep rare disease research knowhow.”

In July, Healx announced that it had raised £10 million ($13 million) in a series A financing which the firm will use to hire staff and “expand its artificial intelligence and machine learning technologies.”